Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FibroGenesis Inks Manufacturing Agreement | Contract Pharma
Breaking News, Collaborations & Alliances

FibroGenesis Inks Manufacturing Agreement

Engages CDMO iBiologics to manufacture proprietary fibroblasts.

FibroGenesis, a developer of fibroblast-based therapeutic solutions for unmet medical needs, has entered into a manufacturing agreement with iBiologics to supply its proprietary allogeneic fibroblast cells to support FibroGenesis’s growing chronic disease platform and ongoing clinical trials.
 
“We are extremely pleased to partner with iBiologics to manufacture our breakthrough fibroblasts,” said Pete O’Heeron, chief executive officer, FibroGenesis. “Our collaboration with iBiologics has produced the highest quality fibroblasts available and their adherence to GMP processes assures us of a reliable source for this unique cell line which will ultimately help patients suffering from chronic diseases.”
 
Francisco Silva, chief executive officer, iBiologics, said, “FibroGenesis has a unique and impressive platform technology and is positioned to secure its place as a premier provider of cell-based therapeutics and we look forward to being part of this process.”
 
iBiologics is a contract development and manufacturing organization (CDMO) for the development and manufacturing of autologous and allogeneic cell and gene therapy products.  It provides a combination of custom services to companies across all points of translational and clinical development.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters